comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 21:54:55 - browse：6

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Travis Kelce and the trap of celebrity vaccine endorsements

WSS

Key Senate panel to consider PBM, drug pricing reform package

Inari Medical to buy amputation prevention company LimFlow

Donald Trump's relentless attacks on special counsel Jack Smith

Bill would allow buprenorphine prescription for addiction via telehealth

Readout LOUD podcast: ESMO highlights & Roivant's big deal

DeepMind touts AlphaFold's new skills as protein folding AI models face off

hotspot

comprehensive

leisure time

Supreme Court strikes down use of affirmative action

Bill would allow buprenorphine prescription for addiction via telehealth

Duchenne breakthrough therapy leaves behind pioneering families

Lung cancer screening guidelines updated for cigarette smokers

Supreme Court strikes down use of affirmative action

Infant mortality in U.S. rose last year for first time in decades: CDC

In Memoriam: Notable people who died in 2023

Explaining an after

What does generative AI mean for health care? We asked experts

What is microchimerism and how does it affect maternal health?

hotspot

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Medicare must police algorithms in Medicare Advantage, Dems say

Colonoscopy at 40? Study finds a possible benefit

The strategy behind pharma's lawsuits over drug pricing reform

Colonoscopy at 40? Study finds a possible benefit

Gene therapy’s promise and the high cost of hope

Wikipedia

hotspot

leisure time

explore